Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ARGX
ARGX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ARGX News
FDA Approves VYVGART for All Adult gMG Patients
2d ago
Newsfilter
FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis
1d ago
seekingalpha
argenx SE Q1 Earnings Beat Expectations
3d ago
seekingalpha
argenx CEO to Present at BofA Healthcare Conference
4d ago
Newsfilter
argenx SE to Announce Q1 Earnings on May 7
4d ago
seekingalpha
argenx to Host Q1 2026 Financial Results Conference Call on May 7
Apr 30 2026
Newsfilter
VYVGART Shows Significant Symptom Improvement in Ocular Myasthenia Gravis Treatment
Apr 18 2026
Newsfilter
Analysis of IBB ETF Trading Dynamics
Mar 11 2026
NASDAQ.COM
Dianthus Therapeutics Early Decision Boosts Stock Surge
Mar 09 2026
stocktwits
VYVGART Shows Promise as Targeted Treatment for Ocular Myasthenia Gravis
Mar 06 2026
Newsfilter
argenx SE Reports Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis
Mar 06 2026
Yahoo Finance
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
Argenx Reports Strong Q4 Results and Positive Phase 3 Study Outcomes
Feb 27 2026
Benzinga
Argenx Reports Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis
Feb 26 2026
Benzinga
Argenx Reports Positive Phase 3 Results for Vyvgart in Eye Disease
Feb 26 2026
Newsfilter
argenx SE Q4 Earnings Beat Expectations with Strong Revenue Growth
Feb 26 2026
seekingalpha
Show More News
